FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Evelyne Ségal-Bendirdjian

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Acute Promyelocytic Leukemia

Physiology

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Eric Nguyen; Frédéric Pendino; Stein Ove Døskeland; Gro Gausdal; Michel Lanotte; Jacqueline Varennes; Evelyne Ségal-Bendirdjian
Activation of Both Protein Kinase A (PKA) Type I and PKA Type II Isozymes Is Required for Retinoid-Induced Maturation of Acute Promyelocytic Leukemia Cells.
Mélanie Chtchigrovsky; Thierry CRESTEIL; Laure Eloy; Hélène Jullien; Joel Poupon; Pascal Retailleau; Lina Saker; Evelyne Ségal-Bendirdjian; Sophie Bombard; Angela Marinetti
Antitumor trans-N-heterocyclic carbene-amine-Pt(II) complexes: synthesis of dinuclear species and exploratory investigations of DNA binding and cytotoxicity mechanisms.
G Gausdal; Bjorn T Gjertsen; U Havemann; Lars Herfindal; Rune Kleppe; Michel Lanotte; Emmet McCormack; E Nguyen; Frédéric Pendino; N Rouhee; Frank Schwede; Evelyne Ségal-Bendirdjian; Jørn Skavland; A Wergeland; Oystein Bruserud; Stein Ove Døskeland
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Evelyne Ségal-Bendirdjian (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Eric Nguyen; Frédéric Pendino; Stein Ove Døskeland; Gro Gausdal; Michel Lanotte; Jacqueline Varennes; Evelyne Ségal-Bendirdjian
Activation of Both Protein Kinase A (PKA) Type I and PKA Type II Isozymes Is Required for Retinoid-Induced Maturation of Acute Promyelocytic Leukemia Cells.
Molecular pharmacology 2013;83(5):1057-65.
2013: Mélanie Chtchigrovsky; Thierry CRESTEIL; Laure Eloy; Hélène Jullien; Joel Poupon; Pascal Retailleau; Lina Saker; Evelyne Ségal-Bendirdjian; Sophie Bombard; Angela Marinetti
Antitumor trans-N-heterocyclic carbene-amine-Pt(II) complexes: synthesis of dinuclear species and exploratory investigations of DNA binding and cytotoxicity mechanisms.
Journal of medicinal chemistry 2013;56(5):2074-86.
2013: G Gausdal; Bjorn T Gjertsen; U Havemann; Lars Herfindal; Rune Kleppe; Michel Lanotte; Emmet McCormack; E Nguyen; Frédéric Pendino; N Rouhee; Frank Schwede; Evelyne Ségal-Bendirdjian; Jørn Skavland; A Wergeland; Oystein Bruserud; Stein Ove Døskeland
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Cell death & disease 2013;4():e516.
2012: Mona Samy; Jean Bénard; Sophie Bombard; Sétha Douc-Rasy; Charles-Henry Gattolliat; Josette Hillion; Eric Nguyen; Frédéric Pendino; Evelyne Ségal-Bendirdjian
Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant.
Molecular cancer therapeutics 2012;11(11):2384-93.
2012: Jean-Luc Carrier; Pasha Javadi; Emilie Bourrier; Céline Camus; Evelyne Ségal-Bendirdjian; Aïda Karniguian
cFos mediates cAMP-dependent generation of ROS and rescue of maturation program in retinoid-resistant acute promyelocytic leukemia cell line NB4-LR1.
PloS one 2012;7(11):e50408.
2011: Laure Deville; Josette Hillion; Frédéric Pendino; Mona Samy; Eric Nguyen; Evelyne Ségal-Bendirdjian
hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications.
Molecular cancer therapeutics 2011;10(5):711-9.
2010: Eric Gilson; Evelyne Ségal-Bendirdjian
The telomere story or the triumph of an open-minded research.
Biochimie 2010;92(4):321-6.
2009: Frédéric Pendino; Eric Nguyen; Inge Jonassen; Bjarte Dysvik; Abdulkader Azouz; Michel Lanotte; Evelyne Ségal-Bendirdjian; Johan R Lillehaug
Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis.
Blood 2009;113(14):3172-81.
2009: Laure Deville; Josette Hillion; Evelyne Ségal-Bendirdjian
Telomerase regulation in hematological cancers: a matter of stemness?
Biochimica et biophysica acta 2009;1792(4):229-39.
2008: Evelyne Ségal-Bendirdjian; Eric Gilson
Telomeres and telomerase: from basic research to clinical applications.
Biochimie 2008;90(1):1-4.
2006: Ying-Li Wu; Charles Dudognon; Eric Nguyen; Josette Hillion; Frédéric Pendino; Ilona Tarkanyi; Janos Aradi; Michel Lanotte; Jian-Hua Tong; Guo-Qiang Chen; Evelyne Ségal-Bendirdjian
Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths.
Journal of cell science 2006;119(Pt 13):2797-806.
2006: Laure Deville; Josette Hillion; Michel Lanotte; Philippe Rousselot; Evelyne Ségal-Bendirdjian
Diagnostics, prognostic and therapeutic exploitation of telomeres and telomerase in leukemias.
Current pharmaceutical biotechnology 2006;7(3):171-83.
2006: Frédéric Pendino; Josette Hillion; Charles Dudognon; J Delaunay; SAMIA MOURAH; Marie-Pierre Podgorniak; I Lafon; Christine Chomienne; Michel Lanotte; Hervé Dombret; Philippe Rousselot; Evelyne Ségal-Bendirdjian
Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL.
Leukemia 2006;20(4):599-603.
2006: Frédéric Pendino; Ilona Tarkanyi; Charles Dudognon; Josette Hillion; Michel Lanotte; Janos Aradi; Evelyne Ségal-Bendirdjian
Telomeres and telomerase: Pharmacological targets for new anticancer strategies?
Current cancer drug targets 2006;6(2):147-80.
2005: Ilona Tarkanyi; Charles Dudognon; Josette Hillion; Frédéric Pendino; Michel Lanotte; Janos Aradi; Evelyne Ségal-Bendirdjian
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
Leukemia 2005;19(10):1806-11.
2005: Ilona Tarkanyi; András Horváth; Istvan Szatmari; Helga Eizert; György Vámosi; Sándor Damjanovich; Evelyne Ségal-Bendirdjian; Janos Aradi
Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide.
FEBS letters 2005;579(6):1411-6.
2005: Evelyne Ségal-Bendirdjian; Charles Dudognon; Julie Mathieu; Josette Hillion; Françoise Besançon
[Cell death signalling: recent advances and therapeutic application].
Bulletin du cancer 2005;92(1):23-35.
2004: Charles Dudognon; Frédéric Pendino; Josette Hillion; Anne Saumet; Michel Lanotte; Evelyne Ségal-Bendirdjian
Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance.
Oncogene 2004;23(45):7469-74.
2003: Frédéric Pendino; Charles Dudognon; François Delhommeau; Tewfik Sahraoui; Maria Flexor; Annelise Bennaceur-Griscelli; Michel Lanotte; Evelyne Ségal-Bendirdjian
Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death.
Oncogene 2003;22(57):9142-50.
2003: Chafké Ahmed Belmokhtar; Josette Hillion; Charles Dudognon; Susana Fiorentino; Maria Flexor; Michel Lanotte; Evelyne Ségal-Bendirdjian
Apoptosome-independent pathway for apoptosis. Biochemical analysis of APAF-1 defects and biological outcomes.
The Journal of biological chemistry 2003;278(32):29571-80.
2003: Evelyne Ségal-Bendirdjian; Josette Hillion; Chafké Ahmed Belmokhtar
[Current concepts on apoptotic signalling pathways: new targets for anticancer strategies].
Bulletin du cancer 2003;90(1):9-17.
2002: Frédéric Pendino; Tewfik Sahraoui; Michel Lanotte; Evelyne Ségal-Bendirdjian
A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation.
Leukemia 2002;16(5):826-32.
2001: GR Benoit; M Roussel; Frédéric Pendino; Evelyne Ségal-Bendirdjian; Michel Lanotte
Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation.
Oncogene 2001;20(49):7161-77.
2001: GR Benoit; Maria Flexor; Françoise Besançon; Lucia Altucci; Aurélie Rossin; Josette Hillion; Zoltán Balajthy; Luc LEGRES; Evelyne Ségal-Bendirdjian; Hinrich Gronemeyer; Michel Lanotte
Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells.
Molecular endocrinology (Baltimore, Md.) 2001;15(7):1154-69.
2001: Chafké Ahmed Belmokhtar; Josette Hillion; Evelyne Ségal-Bendirdjian
Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms.
Oncogene 2001;20(26):3354-62.
2000: P Séité; S Ruchaud; Josette Hillion; M C Gendron; O Bruland; Evelyne Ségal-Bendirdjian; S O Doskeland; Johan R Lillehaug; Michel Lanotte
Ectopic expression of Bcl-2 switches over nuclear signalling for cAMP-induced apoptosis to granulocytic differentiation.
Cell death and differentiation 2000;7(11):1081-9.
2000: Chafké Ahmed Belmokhtar; Alicia Torriglia; Marie-France Counis; Yves Courtois; Alain Jacquemin-Sablon; Evelyne Ségal-Bendirdjian
Nuclear translocation of a leukocyte elastase Inhibitor/Elastase complex during staurosporine-induced apoptosis: role in the generation of nuclear L-DNase II activity.
Experimental cell research 2000;254(1):99-109.
1998: Evelyne Ségal-Bendirdjian; L Mannone; Alain Jacquemin-Sablon
Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance.
Cell death and differentiation 1998;5(5):390-400.